The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.

scientific article published on 26 July 2014

The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/RHEUMATOLOGY/KEU273
P8608Fatcat IDrelease_zvk3dkguprbu3a7jqghx4naxq4
P698PubMed publication ID25065010
P5875ResearchGate publication ID264290578

P50authorJames M BrewerQ37385291
Iain McInnesQ41687181
Robert A BensonQ58382147
P2093author name stringPaul Garside
Martin Braddock
Andrew M Platt
John P Butcher
Ross McQueenie
P2860cites workEngagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activationQ24675931
T-cell priming by dendritic cells in lymph nodes occurs in three distinct phasesQ28237805
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid ArthritisQ28294375
ICOS is essential for effective T-helper-cell responsesQ28594859
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammationQ29614224
The pathogenesis of rheumatoid arthritisQ29614957
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrowQ29615498
Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical featuresQ33551716
Therapeutic targeting of Syk in autoimmune diabetesQ34308759
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivoQ34440540
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammationQ34562439
Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritisQ34896320
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis riskQ35125868
Immune complexes in sera and synovial fluids of patients with rheumatoid arthritis. Radioimmunoassay with monocylonal rheumatoid factorQ35195563
Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritisQ35821357
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalizationQ36367948
Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profilesQ36512352
The SYK tyrosine kinase: a crucial player in diverse biological functionsQ36662082
Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammationQ37101076
Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsivenessQ37144550
Evidence that cytokines play a role in rheumatoid arthritisQ37316594
T cells in rheumatoid arthritisQ37324840
Common variants at CD40 and other loci confer risk of rheumatoid arthritisQ37376871
T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.Q42767257
Identifying the cells breaching self-tolerance in autoimmunityQ43978140
A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation.Q44272104
A novel Syk kinase-selective inhibitor blocks antigen presentation of immune complexes in dendritic cellsQ45157810
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trialQ46271720
An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupusQ46625173
Characterization of CD4+ T-cell-dendritic cell interactions during secondary antigen exposure in tolerance and priming.Q51888898
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.Q54579373
In Vivo Generated Th1 Cells Can Migrate to B Cell Follicles to Support B Cell ResponsesQ58867363
P433issue1
P921main subjectdendritic cellQ506253
P304page(s)169-177
P577publication date2014-07-26
P1433published inRheumatologyQ7320492
P1476titleThe active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
P478volume54

Reverse relations

cites work (P2860)
Q54144290Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Q36087431Kinases: a remote control in inflammasome activity
Q48120395The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.

Search more.